Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

Inclusion Criteria: * patients with high grade cervical intraepithelial lesions (CIN2/3) * patients whose lesions are HPV16+ * patients who are age 18 or older * patients who are able to give informed consent * patients who are immunocompetent * patients who are not pregnant, committed to using adequate contraception if of childbearing age * patients who have a minimum hemoglobin level of 9 Exclusion Criteria: * Patients with cytologic evidence of glandular dysplasia * Patients with cytologic evidence of adenocarcinoma in situ * Patients who are pregnant * Patients with an active autoimmune disease * Patients who are taking immunosuppressive medication * Patients with concurrent malignancy except for nonmelanoma skin lesions * Patients who have an allergy to gold. * Patients with any evidence of damaged skin, or moles, scars, tattoos or marks at the proposed site(s) of administration that might interfere with the interpretation of local skin reactions. * History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed site of administration in the past 5 years. * Patients who have an active autoimmune disease or history of autoimmune disease requiring medical treatment with systemic immunosuppressants, including: inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemic, or immune thrombocytopenia, rheumatoid arthritis…